Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material

An antibody-directed enzyme prodrug therapy (ADEPT) system against CEA-positive tumours is currently in phase I clinical trials. It consists of a prodrug, 4-[N,N-bis(2-iodoethyl) amino] phenoxycarbonyl L -glutamic acid (ZD2767P) and a conjugate of the F(ab')(2) anti-CEA antibody A5B7 and the ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Webley, S D, Francis, R J, Pedley, R B, Sharma, S K, Begent, R H J, Hartley, J A, Hochhauser, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363686/
https://www.ncbi.nlm.nih.gov/pubmed/11401322
http://dx.doi.org/10.1054/bjoc.2001.1843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363686/
https://www.ncbi.nlm.nih.gov/pubmed/11401322
http://dx.doi.org/10.1054/bjoc.2001.1843

Ejemplares similares